Welcome to our dedicated page for Journey Medical news (Ticker: DERM), a resource for investors and traders seeking the latest updates and insights on Journey Medical stock.
Journey Medical Corp (DERM) is a commercial-stage pharmaceutical leader specializing in dermatology treatments. This page aggregates official announcements and verified updates about DERM's prescription drug developments, financial performance, and regulatory progress.
Find categorized press releases covering FDA approvals, clinical trial results, partnership agreements, and earnings disclosures. Investors gain streamlined access to strategic updates impacting DERM's position in the $7.3B U.S. dermatology pharmaceuticals market.
Key resources include product launch timelines, research collaboration details, and analysis of DERM's branded/generic medication portfolio. Content is rigorously curated to support informed decision-making without promotional bias.
Bookmark this page for efficient tracking of DERM's advancements in treating acne, rosacea, and other skin conditions through FDA-cleared therapies.
Journey Medical Corporation (NASDAQ: DERM) has enrolled over 50% of participants in its Phase 3 trials evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for treating papulopustular rosacea. This milestone indicates progress in collaboration with Dr. Reddy’s Laboratories. The company anticipates topline data in early 2023, followed by a New Drug Application filing later that year, expecting DFD-29 to achieve peak annual sales exceeding $100 million. Previous Phase 2 trials showed DFD-29's efficacy nearly double that of doxycycline in reducing inflammatory lesions.
Journey Medical reported a 20% increase in net revenue for Q2 2022, totaling $18.3 million, compared to $15.3 million in Q2 2021. This growth was supported by settlement agreements with Padagis ensuring exclusivity for key products. Enrollment in the DFD-29 Phase 3 trials is progressing, with top-line data expected in early 2023 and an NDA filing anticipated in the second half of 2023. Despite a $7.5 million net loss, there was an improved Non-GAAP Adjusted EBITDA loss of $(2.6) million. The company’s cash reserves are at $38.1 million.
Journey Medical Corporation (NASDAQ: DERM) will release its Q2 2022 financial results on August 9, 2022, after market close. A conference call will follow at 4:30 p.m. ET, allowing investors to discuss the results and receive a corporate update. Interested participants can dial in 10 minutes early and join the call. A live audio webcast will also be available on their website, with a replay option for 30 days. Journey Medical focuses on developing and commercializing dermatology products, with nine marketed treatments currently.
Journey Medical (NASDAQ: DERM) announced a settlement with Padagis US LLC regarding patents for three key products: QBREXZA, AMZEEQ, and ZILXI. Under the agreement, Padagis cannot launch generics until August 15, 2030, July 1, 2031, and April 1, 2027, respectively. This settlement is aimed at solidifying Journey Medical's market exclusivity and supporting sales growth for these dermatological products. The CEO emphasized the importance of enforcing intellectual property rights to benefit the company, shareholders, and patients relying on these treatments.
Journey Medical Corporation (NASDAQ: DERM), a pharmaceutical company specializing in dermatology, will present at the B. Riley Securities 22nd Annual Institutional Investor Conference on May 26, 2022. CEO Claude Maraoui will provide a corporate overview at 12:20 p.m. PT and will engage in one-on-one meetings during the event. Journey Medical focuses on innovative dermatology products and currently markets nine such products. Founded by Fortress Biotech (NASDAQ: FBIO), the company is headquartered in Scottsdale, Arizona.
Journey Medical Corporation (NASDAQ: DERM) reported record revenue of $23.3 million for Q1 2022, a 117% increase compared to Q1 2021. Net product sales reached $20.8 million, up 94% year-over-year. The company initiated a pivotal Phase 3 clinical trial for DFD-29 targeting papulopustular rosacea and expects NDA filing in H2 2023. Although DERM reported a net loss of $1.4 million, its Adjusted EBITDA improved to $2.3 million. Journey Medical aims to launch another prescription product in H2 2022, underlining its growth strategy.
Journey Medical Corporation (NASDAQ: DERM) will release its Q1 2022 financial results on May 10, 2022, post-market. A conference call is scheduled for that day at 4:30 p.m. ET. Interested parties can join via dial-in or a live audio webcast, with replays available for 30 days. Journey Medical focuses on dermatological products and currently markets nine such products. The company, founded by Fortress Biotech (NASDAQ: FBIO), aims to commercialize innovative solutions in dermatology.
Journey Medical Corporation (NASDAQ: DERM) announced participation in the Fortress Biotech Virtual R&D Summit on April 5-6, 2022. The management team will present a corporate overview and engage in a panel discussion on April 5 at 1:30 p.m. ET. The event, hosted by the B. Riley Securities’ Healthcare Equity Research team, will showcase Fortress’ diverse pipeline. A webcast of the presentation will be available on Journey Medical's website for 30 days post-event. Journey Medical focuses on innovative dermatology products and has nine marketed treatments for skin conditions.
Journey Medical Corporation (NASDAQ: DERM) announced its financial results for the full year 2021, reporting a record net product revenue of $63.1 million, a 42% increase from 2020. The company also successfully completed its IPO, raising $30.6 million. DERM initiated a pivotal Phase 3 clinical program for DFD-29 aimed at treating papulopustular rosacea. Despite these advancements, the company reported a net loss of $44 million for the year, largely attributed to R&D expenses and cybersecurity losses.
Journey Medical Corporation (NASDAQ: DERM) plans to release its year-end 2021 financial results on March 23, 2022, following the U.S. market close. A conference call to discuss these results will take place on the same day at 4:30 p.m. ET. Interested individuals can participate by dialing the provided numbers or joining the live audio webcast available on the company’s website. Journey Medical focuses on the development and commercialization of dermatological products and has nine products currently in the market.
FAQ
What is the current stock price of Journey Medical (DERM)?
What is the market cap of Journey Medical (DERM)?
